SCHEMBL439217

SCHEMBL439217

O=C(O)C1CCC(C(=O)c2ccccc2)CC1

nearest known ligand 0.66

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
HTR2A P28223 1/20 0.51
CPB1 P15086 1/20 0.51
MGLL Q99685 2/20 0.50
KMT2A Q03164 2/20 0.50
HSD11B1 P28845 1/20 0.50
AKR1C3 P42330 1/20 0.50
AKR1C1 Q04828 1/20 0.50
MEN1 O00255 1/20 0.50
SLC18A3 Q16572 2/20 0.49
CES2 O00748 1/20 0.48
CES1 P23141 1/20 0.48
KCNH2 Q12809 1/20 0.47
ALDH1A1 P00352 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL407216 1.00 NPC1 (0.52) NPC1RAB9AHTR2ACPB1MGLL
SCHEMBL3515355 1.00 NPC1 (0.52) NPC1RAB9AHTR2ACPB1MGLL
SCHEMBL18428493 0.93 HTR2A (0.56) HTR2ACPB1MGLLKMT2AHSD11B1
SCHEMBL324342 0.93 HTR2A (0.56) HTR2ACPB1MGLLKMT2AHSD11B1
Bicarbonate SCHEMBL11468689 0.91 HTR2A (0.54) HTR2ACPB1MGLLKMT2AHSD11B1
SCHEMBL2980744 0.88 AKR1C3 (0.56) NPC1RAB9AHTR2ACPB1MGLL
SCHEMBL2980743 0.88 AKR1C3 (0.56) NPC1RAB9AHTR2ACPB1MGLL
SCHEMBL2980746 0.88 AKR1C3 (0.56) NPC1RAB9AHTR2ACPB1MGLL
Acetic Acid SCHEMBL2762930 0.87 HTR2A (0.51) NPC1RAB9AHTR2ACPB1MGLL
SCHEMBL26883 0.85 SLC18A3 (0.51) HTR2ACPB1MGLLKMT2AHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10172378-B2 Mono- or bicyclic carboxylic acids as off-note blockers GIVAUDAN, SA (CH) 2019-01-08 US disclosed
EP-2185007-B1 MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS GIVAUDAN SA (CH) 2018-05-23 EP disclosed
US-20160205978-A1 MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS GIVAUDAN SA (CH) 2016-07-21 US disclosed
US-20120065196-A1 AMIDE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-15 US disclosed
US-20120065196-A1 AMIDE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-15 US disclosed
US-20100311786-A1 MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS GIVAUDAN SA (CH) 2010-12-09 US disclosed
EP-2185007-A2 MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS Givaudan SA (CH) 2010-05-19 EP disclosed
WO-2009015504-A2 MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS GIVAUDAN SA (CH) 2009-02-05 WO disclosed
WO-2008011130-A2 AMIDE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 WO disclosed
WO-2008011130-A2 AMIDE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311786-A1 MONO- OR BICYCLIC CARBOXYLIC ACIDS AS OFF-NOTE BLOCKERS SORD, GLUL, ASNS NPC1 2443/4885RAB9A 2876/4885HTR2A 4474/4885
US-20120065196-A1 AMIDE COMPOUNDS DGAT2, DGAT1, DLAT NPC1 142/4885RAB9A 1525/4885HTR2A 3673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.